StreetAlpha.app
Home › Stocks › CTNM

Contineum Therapeutics, Inc. (CTNM)

Healthcare
$8.68
▼ −3.98%
LAST CLOSE · NOV 20

Contineum Therapeutics develops small molecule drugs for lung fibrosis, chronic pain, depression and multiple sclerosis. It last closed at $8.68 on Nov 20, down 3.98% on the day. The next earnings report for CTNM is expected around Thu, Mar 4, 2027, after the close. For the quarter ended Sep 2026, CTNM reported EPS of -$0.49. Over its last 8 reports the stock moved an average of 3.1% the session after earnings. Over the last 12 months CTNM insiders bought $0 of stock on the open market and sold $1.9M, according to SEC Form 4 filings.

AI Auto Pilots
Is CTNM in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold CTNM.

Key Stats

Last 12 months
Results
Net income
−$63.5M
EPS (diluted)
−$1.77
Free cash flow
−$52.2M
Balance sheet
Cash & equivalents
$75.2M
At Sep 30
Shareholder equity
$245.4M
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2023: $22.7M$22.7MFY2023FY2024: −$42.3M−$42.3MFY2024FY2025: −$60.0M−$60.0MFY2025

From CTNM's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 3). Last 12 months adds up the four latest quarters.

Next report
Mar 4
Estimated date · After the close
Reported EPS
-$0.49
Quarter ended Sep 2026
Year ago EPS
-$0.45
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.57Dec '24Mar 2025: -$0.62Mar '25Jun 2025: -$0.62Jun '25Sep 2025: -$0.45Sep '25Dec 2025: -$0.49Dec '25Mar 2026: -$0.39Mar '26Jun 2026: -$0.40Jun '26Sep 2026: -$0.49Sep '26Latest -$0.49
Revenue by quarter
Not enough quarters on file yet.
How CTNM moved after its last 8 reports
Average move the session after a report ±3.1%
Nov 3, 2026After the close+1.0%
Jul 30, 2026After the close−1.6%
May 5, 2026After the close+3.8%
Mar 5, 2026After the close+0.5%
Oct 30, 2025After the close+4.5%
Aug 5, 2025After the close+5.5%
May 14, 2025After the close+2.6%
Mar 6, 2025After the close+5.1%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on CTNMStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on CTNM
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on CTNM

Technical Analysis

CTNM · as of the Nov 20 close · updated each morning
Downtrend

The stock is 9% below its 20 day and 23% below its 50 day average. It is 53% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 39). The nearest support is the swing low (Nov 6) at $8.59, and the nearest resistance the Pivot at $8.76.

Short trendBearish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityNormal, 9.1%/day
Key levels
$17.7952 week high+105.0%
$13.27200 day average+52.9%
$13.00100 day average+49.8%
$10.6650 day average+22.8%
$9.4920 day average+9.3%
$9.03Pivot R1+4.0%
$8.79Swing high (Oct 21)+1.3%
$8.76Pivot+0.9%
$8.68Last close
$8.59Swing low (Nov 6)−1.0%
$8.42Pivot S1−3.0%
$6.7252 week low−22.6%
Indicators
RSI (14)38.98Weak, oversold below 30Neutral
MACD-0.32Above its signal lineBullish
Stochastic18.3Near the bottom of its rangeOversold
ADX (14)21.1Weak trend
Williams %R-92.5Oversold below −80, overbought above −20Oversold
CCI (20)-109.0Oversold below −100, overbought above 100Oversold
Rate of change−8.8%Change over 10 sessionsBearish
ATR (14)$0.79Typical daily range, 9.1% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for CTNM

What happened before

See how CTNM did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Whale Options Flow

90D
Whale options flow for CTNMHow many large options trades hit CTNM, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

CTNM Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲72 buying vs 37 selling
  • ▲Held by funds +16.9 pts
  • ▲Funds holding +17
  • ▼Superinvestors: 0 added, 4 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding119102+16.7%
In funds' top 10440.0%
Held by funds149.2%132.2%+16.9 pts
New / increased28 / 4428 / 32+20.0%
Reduced / sold out26 / 1119 / 15+8.8%
Put/call ratio0.25––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See CTNM institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

CTNM Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$1.9M22 sales · 3 insiders
100% of the selling was under pre-arranged trading plans.
2025-12 sold $95K2026-01 sold $95K2026-02 sold $321K2026-03 sold $117K2026-04 sold $56K2026-05 sold $55K2026-06 sold $389K2026-07 sold $651K2026-08 sold $40K2026-09 sold $41KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Sep 8Carmine N. StengoneCEO and PresidentSale plan2,500$16.46$41K
Aug 3Carmine N. StengoneCEO and PresidentSale plan2,500$16.01$40K
Jul 9Daniel S. LorrainChief Scientific OfficerSale plan1,040$16.00$17K
Jul 8Carmine N. StengoneCEO and PresidentSale plan2,500$16.00$40K
Jul 1Daniel S. LorrainChief Scientific OfficerSale plan37,179$15.99$595K
Jun 30Carmine N. StengoneCEO and PresidentSale plan10,000$16.01$160K
Every insider buy and sale for CTNM over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See CTNM insider trades →

From SEC Form 4 filings by CTNM's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CTNM is in one of them and how their past CTNM trades turned out.

CTNM in the AI portfolios
Loading…

CTNM News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered CTNM in an article yet. Here's the latest on the wider market.

CTNM in the news

About Contineum Therapeutics

Contineum Therapeutics is a San Diego, California company developing small molecule drugs for neuroscience and immunology conditions. Its lead candidate, PIPE-791, is being developed as a pill taken once a day for idiopathic pulmonary fibrosis and is also being studied for chronic pain. A second candidate, PIPE-307, is being developed for depression and multiple sclerosis in partnership with Johnson & Johnson. The company's drugs are intended for patients with these conditions, and none are approved for sale yet.

Headquarters
San Diego, CA